{"filing":{"accession_number":"0001193125-26-330730","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-27","primary_document":"d134183d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/d134183d8k.htm"},"events":[{"id":23189,"run_id":20985,"accession_number":"0001193125-26-330730","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23356,"accession_number":"0001193125-26-330730","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:42:16.872513+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23356,"accession_number":"0001193125-26-330730","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:42:16.872513+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-08-03"}]}